Morgan Stanley Sees Transition Year Ahead for Sagent Pharmaceuticals

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on

. In the report, Morgan Stanley noted, “The '14 outlook was lighter than our below- consensus estimates, as tough FDA timelines delay pipeline launches. SCP leverage and a full pipeline should drive '15-16 improvement and keep our medium term model largely intact.” Sagent Pharmaceuticals closed on Tuesday at $19.73.